Skip to main content

Table 4 Number of patients with adverse events in the ETA+MTX and MTX groups according to study phase

From: Early combination therapy with etanercept and methotrexate in JIA patients shortens the time to reach an inactive disease state and remission: results of a double-blind placebo-controlled trial

Phase Group
MTX ETA + MTX
Phase 1 7 patients (21%)
(11 AEs)
4 patients (11%)
(6 AEs)
Phase 2 3 patients (15%)
(3 AEs)
5 patients (11%)
(5 AEs)
Phase 3 3 patients (33%)
(3 AEs)
9 patients (17%)
(14 AEs)
  1. The table shows the number of patients with AE, (rate of patients with AE), (number of AE); AE adverse event, ETA Etanercept, MTX Methotrexate